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Vaccination represents the most effective control measure in the
fight against infectious diseases. Local mucosal immune responses
are critical for protection from, and resolution of, infection by
numerous mucosal pathogens. Antigen processing across mucosal
surfaces is the natural route by which mucosal immunity is gen-
erated, as peripheral antigen delivery typically fails to induce
mucosal immune responses. However, we demonstrate in this
article that mucosal immune responses are evident at multiple
mucosal surfaces after parenteral delivery of Venezuelan equine
encephalitis virus replicon particles (VRP). Moreover, coinoculation
of null VRP (not expressing any transgene) with inactivated influ-
enza virions, or ovalbumin, resulted in a significant increase in
antigen-specific systemic IgG and fecal IgA antibodies, compared
with antigen alone. Pretreatment of VRP with UV light largely
abrogated this adjuvant effect. These results demonstrate that
alphavirus replicon particles possess intrinsic systemic and mucosal
adjuvant activity and suggest that VRP RNA replication is the
trigger for this activity. We feel that these observations and the
continued experimentation they stimulate will ultimately define
the specific components of an alternative pathway for the induc-
tion of mucosal immunity, and if the activity is evident in humans,
will enable new possibilities for safe and inexpensive subunit and
inactivated vaccines.
vaccine vector  Venezuelan equine encephalitis virus  viral immunology 
RNA virus
The control of a number of important infectious diseases byimmunization is arguably one of the most significant accom-
plishments of the 20th century (1). However, other infectious
diseases remain intractable, causing devastating morbidity and
mortality in human populations, especially in resource-poor
countries. Control of these diseases will depend on an expanded
array of affordable and effective vaccine technologies, such as
propagative and nonpropagative expression vectors based on
viral and bacterial genomes. One such technology uses replicon
particles based on the alphavirus Venezuelan equine encepha-
litis virus (VEE). VEE replicon particles (VRP) are potent
inducers of antigen-specific immune responses andor protec-
tion after pathogen or toxin challenge in various animal species
including mice (2, 3), rabbits (4), cats (5), chickens (6), horses
(7), guinea pigs (8), and nonhuman primates (9). Currently, VRP
expressing the gag gene from HIV clade C are in phase-I clinical
trials in the United States and Africa.
VEE virions contain a positive sense RNA genome of 11.5
kb. The four viral nonstructural proteins, which constitute the
enzymatic activity required for RNA replication, are encoded in
the 5 two-thirds of the genome, whereas the viral structural
proteins (capsid, E1, and E2) are expressed from a 26S sub-
genomic mRNA and encoded in the 3 one-third of the genome
(10, 11). VRP are propagation-defective viral particles carrying
a modified VEE genome. The VRP system takes advantage of
the high-level expression of 26S mRNA by replacing the viral
structural genes with a cloned antigen gene (2). Progeny virions
are not produced in VRP-infected cells, as the viral structural
genes are absent from the replicon RNA; however, the replicon
RNA and the mRNA encoding the antigen are expressed at high
levels after infection (2, 12). To facilitate assembly of VRP, the
replicon RNA is coelectroporated into permissive cells with two
defective helper RNAs that lack the viral packaging signal and
provide the structural genes in trans (2, 12).
VRP display a number of attractive features as vaccine
delivery vehicles, including high-level antigen expression in
infected cells (2), efficient in vivo targeting of mouse (13), and
primate (A. West and R.E.J., unpublished work) dendritic cells
(DCs), efficient ex vivo infection of human DCs (14), and safety,
as the vectors are incapable of synthesizing new virion particles
in infected cells (2, 12). One of the most intriguing properties of
VRP is their ability to induce significant protective immunity in
mucosal challenge models, even when the immunization is at a
nonmucosal site (2, 6, 7, 9, 15).
The natural pathway of mucosal immune induction involves
the direct delivery of immunogen to a mucosal surface and local
processing of antigen in specialized aggregates of lymphoid
tissue, termed mucosal inductive sites (16, 17). Stimulated
lymphocytes then migrate to the corresponding mucosal surface
where antigen-specific IgA and IgG are locally produced, and
specific T cells reside to protect that mucosal surface from
pathogen attack (18, 19). We show in this article that, unlike
many vaccine vector systems that rely on mucosal delivery to
access the natural inductive pathway, VRP are capable of
inducing mucosal immune responses after nonmucosal delivery.
Moreover, we demonstrate that this property is experimentally
separable from VRP-driven immunogen production, as soluble
or particulate immunogens can be simply mixed with VRP
expressing an irrelevant transgene, or no transgene at all, to
induce a mucosal response. Therefore, VRP exploit an alterna-
tive pathway for mucosal immune induction that is distinct from
the natural pathway and suggest important applications of VRP
as mucosal and systemic adjuvants in protein subunit or whole
inactivated prophylactic vaccines and in immunomodulatory
therapies for chronic diseases.
Results
VRP Induce Mucosal Immune Responses. Previous reports have
documented the ability of peripherally inoculated VRP to induce
significant protection from virulent mucosal challenge with
influenza virus in mice and chickens (2, 6), simian immunode-
ficiency virus in macaques (9), and equine arteritis virus in horses
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(7). Also, results obtained with intranasal influenza virus chal-
lenge of hemagglutinin (HA)-VRP-immunized mice showed
significantly decreased influenza virus replication in the nasal
epithelium, as determined by influenza-specific plaque assay and
in situ hybridization. (N.L.D., K. Brown, E.M.B.R., A. West, and
R.E.J., unpublished work). Although VRP induced protection of
the mucosal tissue, it was not directly determined whether local
mucosal immune responses contributed to the observed protec-
tion. Typically, mucosal immunity is induced only when antigens
are processed and presented across mucosal surfaces (20);
however, VRP induced protection in these mucosal challenge
models after immunization by a nonmucosal route.
We wanted to determine whether nonmucosal VRP delivery
resulted in the induction of locally produced, mucosal immunity.
Groups of female BALBc mice were immunized in the rear
footpad at weeks 0 and 4 with diluent, 105 infectious units (IU)
of HA-VRP or 10 g of formalin-inactivated influenza virus
(I-Flu), as a non-VRP-vectored influenza antigen. Another
group of animals was immunized in the rear footpad with 10 g
of I-Flu mixed with 105 IU of GFP-VRP, as an irrelevant VRP
control. At various times after the second inoculation (days 3, 7,
10, 14, 18, 21, and 28), groups of three animals were killed, and
the nasal mucosa were harvested for analysis in a lymphoid
culture assay originally developed by Cebra and colleagues (21).
Detection of flu-specific antibody in supernatant fluids from ex
vivo nasal epithelium organ cultures was used as a measure of
mucosal immune induction. Significant antibody production was
not observed in supernatants from nasal epithelium until day 7
postboost and was detectable from day 7 to day 28 postboost. In
comparing nasal antibody production across the range of time
points, we found that VRP-containing inocula induced a statis-
tically significant increase in flu-specific IgA antibodies in organ
cultures from the nasal epithelium, compared with cultures from
animals inoculated with I-Flu alone (HA-VRP compared with
I-Flu, P  0.001; GFP-VRP  I-Flu compared with I-Flu, P 
0.001, data not shown). Shown in Fig. 1 is the day-21 time point.
All three antigen delivery methods were capable of stimulating
local f lu-specific IgG antibody production in nasal mucosa as
detected in the ex vivo supernatants, although VRP-induced
responses were significantly increased compared with responses
induced by delivery of I-Flu alone (Fig. 1 A). HA-VRP and the
delivery of I-Flu mixed with GFP-VRP, but not delivery of I-Flu
alone, induced flu-specific, mucosal IgA antibodies (Fig. 1B).
Also, VRP induced a statistically significant increase in flu-
specific IgG and IgA antibodies present in nasal washes of
immunized animals compared with inoculation of I-Flu alone
(data not shown). These results indicate that (i) VRP are capable
of inducing local, antigen-specific antibody production in mu-
cosal tissues after nonmucosal delivery, (ii) mucosal immune
induction is a property of VRP, as antigen alone fails to induce
significant mucosal IgA responses, and (iii) VRP are capable of
inducing mucosal immunity either when the immunogen is
expressed by the VRP, or when the immunogen is simply mixed
with an irrelevant VRP that appears to serve as an adjuvant.
The mucosal response observed in the nasal epithelium did
not result from an inordinately high systemic response in the
VRP-containing groups. The experimental system was designed
such that the systemic IgG response induced in I-Flu-immunized
animals, as measured by flu-specific IgG antibodies in ex vivo
spleen cultures, was statistically equivalent to the systemic
responses induced by VRP-containing inocula (Fig. 1C). There-
fore, any differences in the mucosal responses could not simply
be attributed to higher immune responses in general. However,
HA-VRP and I-Flu mixed with GFP-VRP induced significantly
greater levels of f lu-specific, systemic IgA antibodies than I-Flu
alone, as measured in spleen culture supernatant fluids (Fig.
1D). Preliminary results with analogous vectors based on Gird-
wood virus and A.R.86 virus, alphaviruses in the Sindbis group,
also suggest induction of mucosal immune responses (J.M.T.,
A.C.W., and M. Heise, unpublished work).
VRP Possess Systemic and Mucosal Adjuvant Activity. The results
reported in Fig. 1 strongly suggest that VRP themselves, inde-
pendent of the expressed gene, are capable of serving as both a
systemic and mucosal adjuvant after nonmucosal delivery. To
confirm this hypothesis, groups of eight animals were immunized
in the rear footpad with 106 IU of VRP not expressing any
transgene (null VRP) mixed with either 0.1 or 1.0 g of I-Flu at
weeks 0 and 4. Although null VRP do not express an inserted
gene behind the 26S promoter, a short 175-nt noncoding mRNA
is predicted from the sequence. Animals were bled 2 weeks
postboost, and flu-specific serum IgG antibodies were analyzed
by ELISA. As shown in Fig. 2, the presence of null VRP in the
inoculum increased the flu-specific systemic antibody response
by up to 44-fold (1.0 g dose of I-Flu). To assess mucosal
antibody responses, fecal extracts were prepared and analyzed
for the presence of flu-specific mucosal antibodies by ELISA
(Fig. 2 B and C). Antibodies present in fecal extracts are almost
exclusively locally produced, with minimal contribution from
serum-derived antibodies (22). Flu-specific fecal IgA antibodies
were barely detectable after immunization with I-Flu alone;
however, the inclusion of null VRP as an adjuvant augmented
those responses by 60 fold (1.0-g dose of I-Flu, IgA). These
data confirm that VRP possess systemic and mucosal adjuvant
activity for a particulate antigen.
To further characterize the adjuvant properties of VRP, the
following experiments used null VRP and a soluble test antigen,
ovalbumin (OVA), rather than a particulate antigen (I-Flu).
Groups of six female BALBc mice were immunized at weeks 0
and 4 with 10 g of OVA, either alone or coinoculated with 106
IU of null VRP, by both parenteral (footpad) and mucosal
Fig. 1. VRP induce mucosal immune responses. Groups of animals were
immunized in the rear footpad with diluent, 10 g of I-Flu (solid bars), 105 IU
of HA-VRP (open bars), or 10 g of I-Flu plus 105 IU of GFP-VRP (hatched bars)
at weeks 0 and 4. Three weeks after the second inoculation, lymphoid organ
cultures were established from the nasal epithelium (A and B) and spleen (C
and D). Culture supernatants were evaluated for flu-specific IgG (A and C) and
IgA antibodies (B and D) by ELISA. Data are presented as the geometric
mean  SEM. *, P  0.05; **, P  0.01; ***, P  0.001 compared with I-Flu
alone, as determined by ANOVA.




























(intranasal) delivery. As shown in Fig. 5, which is published as
supporting information on the PNAS web site, both footpad and
nasal delivery of OVA alone resulted in detectable OVA-specific
serum IgG titers 3 weeks postboost. The coinoculation of null
VRP with OVA increased OVA-specific serum IgG responses by
60- and 1,400-fold after footpad and nasal delivery, respec-
tively. To assess mucosal antibody responses, fecal extracts were
prepared from vaccinated animals before the booster inocula-
tion and at weeks 1, 2, and 3 postboost, and analyzed for the
presence of OVA-specific mucosal IgG and IgA antibodies by
ELISA. Delivery of OVA alone failed to consistently induce
detectable levels of OVA-specific fecal antibodies over back-
ground after either footpad or nasal immunization 3 weeks
postboost. However, the inclusion of null VRP in the inoculum
resulted in an 20- to 60-fold increase in OVA-specific fecal IgG
and IgA antibody titers (Fig. 5 B and C), regardless of the route
of immunization. Taken together, the observations using I-Flu
and OVA confirm the systemic and mucosal adjuvant activity of
VRP after either mucosal or nonmucosal delivery of soluble or
particulate immunogens.
VRP RNA Replication Is a Trigger for Adjuvant ActivityImmune
Induction. The critical VRP-specific parameters that mediate
adjuvant activity are currently undefined. Numerous molecular
sensors are capable of recognizing viral products in virus-
infected cells (23), including members of the toll-like receptor
family (24, 25), and a number of IFN-inducible proteins (26, 27).
We hypothesize that one or more of these pathways might be
involved in recognizing RNA products produced after VRP
infection and might play a critical role in VRP adjuvant activity.
To test the hypothesis that VRP RNA replication is necessary for
adjuvant activity, we treated null VRP with UV light before
inoculation. UV treatment causes the formation of uridine
dimers in the replicon RNA, which blocks both RNA replication
and translation of the input RNA, and allows evaluation of
replication-defective VRP as molecular adjuvants.
Groups of six BALBc mice were inoculated in the rear
footpad at weeks 0 and 4 with 10 g of OVA alone or 10 g of
OVA mixed with (i) 1.0 g of cholera toxin (CT), a known
systemic and mucosal adjuvant used here as a positive control
(28), (ii) 104 IU of null VRP, (iii) 104 IU of null VRP treated with
UV light (UV-VRP), or (iv) 106 IU of null VRP. At 1 week
postboost, serum was harvested from immunized animals and
analyzed for the presence of OVA-specific IgG antibodies by
ELISA. OVA-specific serum IgG titers were increased by 64-
and 114-fold after the codelivery of OVA plus 104 or 106 IU of
VRP, respectively (Table 1, which is published as supporting
information on the PNAS web site). In contrast, codelivery of
OVA and 104 IU of UV-VRP failed to induce a statistically
significant increase in OVA-specific serum IgG antibodies (P 
0.05). These results suggest that viral RNA replication was
required for the immune stimulation observed with null VRP.
Importantly, the adjuvant effect of VRP was comparable to
responses induced by 1.0 g of the control adjuvant, CT, under
these conditions.
To quantitate the number of OVA-specific IgG- and IgA-
secreting cells in spleen and nasal epithelium of the same
animals, single-cell suspensions were prepared and analyzed in
an antibody-secreting cell (ASC) enzyme-linked immunospot
assay (ELISPOT). Increased levels of IgG (Fig. 3A) and IgA
(Fig. 3B) ASCs were present in spleen and nasal epithelium in
the OVA-plus-VRP inoculated animals, compared with the
OVA-alone group, again demonstrating a clear systemic and
mucosal VRP adjuvant activity leading to the local production of
antigen-specific antibodies in both systemic and mucosal tissues.
UV treatment of VRP before inoculation largely abrogated this
effect, indicating the importance of VRP RNA function and also
suggesting that contaminants potentially present in the VRP
Fig. 2. VRP adjuvant activity for particulate antigens. Groups of eight
animals were immunized in the rear footpad with 0.1 or 1.0 g of I-Flu in the
presence (hatched bars) or absence (solid bars) of 106 IU of null VRP at weeks
0 and 4. Two weeks after the second inoculation, flu-specific IgG antibodies
were measured in sera (A) and fecal extracts (B), and flu-specific IgA antibodies
were measured in fecal extracts (C) by ELISA. Data are presented as the
geometric mean  SEM. *, P  0.02; **, P  0.005; ***, P  0.0003 compared
with I-Flu alone, as determined by Mann–Whitney.
Fig. 3. Systemic and mucosal adjuvant activity of UV-treated VRP. Groups of
six animals were immunized in the rear footpad with 10 g of OVA alone or
coinoculated with 1.0 g of CT, 104 IU of null VRP, 104 IU of UV-VRP, or 106 IU
of null VRP at weeks 0 and 4. One week after the second inoculation,
splenocytes (open bars) and nasal lymphocytes (solid bars) were isolated from
immunized animals and analyzed for the presence of OVA-specific IgG-
secreting cells (A) and IgA-secreting cells (B) by ELISPOT. Data are presented as
the geometric mean  SEM. *, P  0.05; **, P  0.01; ***, P  0.001 compared
with OVA alone, as determined by ANOVA.




















preparations (such as LPS) were not responsible for the observed
adjuvant activity. Again, VRP adjuvant activity as measured by
ASC ELISPOT was comparable with that of CT. These results
demonstrate that null VRP can act as a true mucosal adjuvant,
and VRP RNA replication is likely the molecular trigger for the
adjuvant activity.
VRP Adjuvant Activity as Compared with Adjuvant Activity of CpG
DNA. We sought to determine how the VRP adjuvant compared
with another known adjuvant, CpG DNA. Unmethylated CpG
motifs found in bacterial genomes are recognized by the innate
immune system through interactions with TLR9 and increase
immunity to coimmunized antigens in numerous experimental
systems (reviewed in ref. 29). To further characterize the relative
strength of VRP adjuvant activity, groups of eight BALBc mice
were inoculated in the rear footpad at weeks 0 and 4 with 10 g
of OVA alone, 10 g of OVA mixed with 105 IU of null VRP,
or 10 g of OVA mixed with 1.0 g of CpG DNA. Two weeks
after the second inoculation, sera, fecal extracts, and vaginal
lavage samples were prepared from individual animals and
analyzed for the presence of OVA-specific antibodies by ELISA.
Also at 2 weeks postboost, single-cell suspensions were prepared
from spleen and nasal epithelium and analyzed for OVA-specific
ASCs by ASC ELISPOT. As shown in Fig. 4, both VRP and CpG
augmented OVA-specific spleen IgG ASCs compared with OVA
alone (P  0.001 and P  0.05, respectively). Although VRP
adjuvanted systemic OVA responses to a greater extent than
CpG, as measured by spleen ASC, measurement of OVA-
specific serum IgG titers suggested that the CpG and VRP
systemic adjuvant effects were comparable (Table 2, which is
published as supporting information on the PNAS web site).
However, VRP induced a significant adjuvant effect on mucosal
IgA responses in fecal extracts and vaginal washes and in IgA
ASCs in the nasal epithelium (Fig. 4 and Table 2). By each of
these assays, VRP-adjuvanted OVA responses in mucosal tissues
were superior to OVA plus CpG. These data suggest that the
systemic adjuvant activity of VRP is at least as strong as that of
CpG and that VRP possess significantly stronger mucosal ad-
juvant activity.
Discussion
Alphavirus replicon vectors expressing pathogen-derived immu-
nogens have been used extensively as vaccine delivery vehicles
and have proven effective at inducing significant protection from
challenge with a number of important pathogens in experimental
and natural hosts. However, the mechanisms that govern im-
mune induction after vector delivery remain largely unexplored.
We demonstrate in this article that VRP possess inherent im-
munostimulatory properties that are independent of protein pro-
duction. Either irrelevant or null VRP, simply codelivered with
soluble OVA protein or inactivated influenza virions, dramatically
augmented antigen-specific antibody production in both the sys-
temic and mucosal compartments, compared with inoculation of
antigen alone. In work not presented here, VRP systemic and
mucosal adjuvant activity also has been demonstrated with Norwalk
virus-like particles (A. LoBue, J.M.T., R. Baric, and R.E.J., un-
published work), cowpox B5R protein (N. Thornburg, J.M.T., and
R.E.J., unpublished work), and simian immunodeficiency virus
gp120 (A. West, J.M.T., and R.E.J., unpublished work), suggesting
that the VRP adjuvant functions without respect to the antigen. In
the present study we have measured only short-term immunity with
VRP adjuvants. However, VRP used as expression vectors elicited
responses that endured throughout the lifetime of the animal. If we
assume that the immunological parameters that govern VRP as
expression vectors are the same as those that govern immune
induction with VRP as adjuvants, then it is likely that adjuvant-
induced immunity will be equally long-lived.
We demonstrate the adjuvant property of alphavirus replicon
particles for both systemic and mucosal immunity, even when
administered by a nonmucosal route. A number of recent reports
have identified other viral (30–33) and bacterial (34) particles
that possess various types of adjuvant activity when codelivered
with antigen. We speculate that such activity is also likely to play
an important role in immune induction under conditions in
which such particles (including VRP) are engineered as vectors
to express a given immunogen. Although those other reports
document the ability of microbial particles to serve as adjuvants,
no other system has demonstrated mucosal immune induction
after nonmucosal delivery, as is observed with VRP. It will be of
interest to determine whether other viruses are capable of
augmenting mucosal antibody responses after nonmucosal de-
livery, or if this property is unique to VEE.
The natural pathway of mucosal immune induction relies on
antigen processing and presentation at mucosal surfaces and
results in the local production of IgA antibodies at those surfaces
(20, 35). VRP were capable of immune induction via the natural
pathway, as nasal delivery resulted in the induction of mucosal
immunity. However, VRP were also capable of exploiting an
alternative pathway that resulted in mucosal immunity after
nonmucosal inoculation. Although there have been a limited
number of examples where induction of mucosal immunity
occurred after inoculation at a parenteral site (reviewed in refs.
36 and 37), there is little consistency among the several examples,
and none of them is analogous to the null VRP adjuvant activity
described here (38–47). Likewise, induction of mucosal immu-
nity has been demonstrated with alphavirus expression vectors,
but only after immunization (48, 49) or boost (15) at a mucosal
surface, and in none of these instances was the potential for
mucosal adjuvant activity examined.
The mechanism by which VRP trigger mucosal immunity after
nonmucosal delivery is undefined at present. One potential
explanation is that either free VRP, or cells infected by VRP in
the skin (13) or lymph node migrate to a traditional mucosal
inductive site, such as Peyer’s patches or mesenteric lymph node,
and induce local antibody production (36). However, experi-
ments using GFP-VRP have failed to consistently demonstrate
VRP-infected cells in such tissues (E.M.B.R., J.M.T., and R.E.J.,
unpublished work). We favor the hypothesis that the lymph node
draining the site of VRP inoculation develops at least some
functions characteristic of a mucosal inductive site. In support of
this idea, preliminary experiments demonstrate the production
Fig. 4. Systemic and mucosal adjuvant activity of VRP compared with CpG
DNA. Groups of eight animals were immunized in the rear footpad with 10 g
of OVA alone (solid bars) or coinoculated with 105 IU of null VRP (hatched bars)
or 1.0 g of CpG DNA (open bars) at weeks 0 and 4. Two weeks after the second
inoculation, splenocytes were isolated and analyzed for the presence of
OVA-specific IgG ASCs, and nasal lymphocytes were isolated and analyzed for
the presence of OVA-specific IgA ASCs by ELISPOT. Data are presented as the
geometric mean  SEM. *, P  0.001 compared with OVA alone; †, P  0.01
compared with CpG; ‡, P  0.05 compared with CpG.




























of antigen-specific, multimeric IgA in the draining lymph node
(DLN) in response to inoculation of VRP (J.M.T. and R.E.J.,
unpublished work). It needs to be determined whether addi-
tional characteristics of a true mucosal inductive site are present
in the DLN of VRP-inoculated mice. We feel that detailed
examination of this alternative pathway for the induction of
mucosal immunity in the VRP experimental system will con-
tribute to a greater understanding of alphavirus-induced immu-
nity, in particular, and mucosal immunity in general.
The molecular basis for the adjuvant activity likely resides in
the ability of the VRP genome to replicate, given the sensitivity
of adjuvant activity to UV inactivation. We suggest that an
element present during virus replication is recognized in
infected host cells and that this recognition initiates a cascade
of events that ultimately leads to the induction of immunity to
codelivered antigens. The most prominent candidates include
viral RNA andor replicative intermediates and their interac-
tions with components of the innate immune system. A variety
of cellular sentinel molecules exist, such as TLR3 (24), TLR7
(25), Rig-I, MDA-5 (27), protein kinase R, and RNaseL (26),
which are capable of recognizing viral replicative molecules. In
fact, a recent report (50) implicates RNaseL in immune
induction to a tolerant melanoma antigen in an alphavirus
replicon system.
Both transgene-expressing particles and particles lacking a trans-
gene possess adjuvant activity, suggesting that adjuvant activity
neither depends on, nor is inhibited by, the presence of a particular
transgene protein. The VRP constructs lacking a transgene are
predicted to express a short, noncoding RNA. It is unlikely that this
truncated subgenomic RNA, or the presence or activity of the 26S
promoter itself, is responsible for the observed adjuvant activity.
Another formal possibility is that translation of the replicase
proteins is responsible for the activity.
One potential trivial explanation for the adjuvant effect is that it
is mediated by a contaminant present in VRP preparations (such as
LPS). However, two observations strongly suggest that a contam-
inant is not the predominant mechanism of immune activation: (i)
no adjuvant activity was observed after codelivery of identically
treated media from a mock VRP preparation (data not shown), and
(ii) UV treatment of VRP ablated adjuvant activity.
We have compared VRP adjuvant activity to that of CT and
CpG DNA. Results from such comparisons suggest that sys-
temic responses induced by VRP are at least equivalent to that
of both CT and CpG DNA. Moreover, after nonmucosal
delivery VRP mucosal adjuvant activity appears to be com-
parable to that of CT and superior to CpG DNA. A number
of important questions regarding VRP adjuvant activity re-
main to be answered, such as how VRP-induced systemic and
mucosal immune responses compare with those of other
peripherally delivered adjuvants, such as alum, and mucosally
delivered CT and whether VRP act as a systemic and mucosal
T cell adjuvant. These additional comparisons will allow more
accurate evaluations of the relative efficiency of VRP-induced
immune stimulation.
In summary, we have demonstrated two activities of alpha-
virus-derived viral vectors: (i) induction of local mucosal
immune responses after inoculation at a remote, nonmucosal
site and (ii) systemic and mucosal adjuvant activity with
codelivered soluble and particulate immunogens. We feel that
these observations and the continued experimentation they
stimulate will advance a search for adjuvant activity among
other viruses and viral vectors, will ultimately define the
specific components of an alternative pathway for the induc-
tion of mucosal immunity, and if the activity is evident in
humans, will enable new possibilities for safe and inexpensive
subunit and inactivated vaccines.
Materials and Methods
VEE Replicon Constructs. The construction and packaging of VRP
have been described (2, 51). The replicon constructs used in
this study were (i) replicons expressing GFP (GFP-VRP), (ii)
replicons expressing the HA gene from inf luenza virus (HA-
VRP), and (iii) replicons that lack a functional transgene
downstream of the 26S promoter (null VRP). Null VRP
contain the viral nonstructural genes, 14 nt of VEE sequence
downstream of the 26 mRNA transcription start site, an
inserted 43-nt-long multiple cloning site, and the 118-nt 3
UTR. All replicon particles used in this study were packaged
in the wild-type (V3000) envelope (2).
Animals and Immunizations. Seven- to 8-week-old female BALBc
mice were immunized either in the rear footpad or intranasally
at weeks 0 and 4. Grade V chicken egg albumin (OVA) was
purchased from Sigma, CT was purchased from List Biological
Laboratories (Campbell, CA), and CpG DNA (ODN 1826) was
purchased from Invivogen (Montreal). Formalin-I-Flu (Charles
River Laboratories) was dialyzed against PBS in a Slidalyzer
cassette (Pierce) according to the manufacturer’s guidelines
before immunization.
Inactivation of VRP by UV Treatment. Null VRP preparations were
diluted to a concentration of 106 unitsml, and 0.2-ml aliquots
were placed in individual wells in a 48-well tissue culture plate.
The plates were exposed to a UV lamp (Sun-Kraft, Chicago) at
a distance of 5 cm for 20 min. No VRP-infected cells were
detectable in vitro after infection of baby hamster kidney cells
with undiluted UV-VRP (data not shown).
Sample Collection. Animals were bled either from the tail vein or
after cardiac puncture, and sera were analyzed by ELISA (see
below). Preparation of fecal extracts was modified from Bradney
et al. (52). Vaginal lavage was performed by washing the exterior
vaginal opening with 0.07 ml of PBS 8–10 times.
Lymphoid Organ Cultures. Lymphoid cultures, originally devel-
oped by Cebra and colleagues (21), were modified from Coffin
et al. (53). Brief ly, spleen and nasal tissue were dissected from
immunized animals and washed three times by aspiration and
resuspension. Nasal tissue from individual animals was placed
in a well of a 48-well tissue culture plate containing 0.3 ml of
media and incubated at 37°C for 7 days at which time super-
natants were harvested.
ELISA. ELISAs for influenza- and OVA-specific antibodies were
performed according to standard ELISA methods (2). Antibody
endpoint titers are reported as the reciprocal of the highest
dilution that resulted in an OD450  0.2. In lymphoid culture
supernatants, endpoint titers for flu-specific IgA are reported as
the reciprocal of the highest dilution that results in an OD450
reading at least 2 SDs greater than values obtained from
mock-vaccinated animals.
ASC ELISPOT. Single-cell suspensions were prepared from both
spleen and nasal epithelium. Whole spleens were disrupted be-
tween frosted glass slides, and red blood cells were lysed after
addition of ammonium chloride buffer. Cells were washed and
placed on a Lympholyte-M density gradient. Banded cells were
harvested, washed, and counted. For preparation of nasal lympho-
cytes, nasal tissue from the tip of the nose to just anterior of the eye
sockets was harvested from immunized animals, and the upper
palate, including the nasal-associated lymphoid tissue, was carefully
removed. Nasal tissue was physically disrupted and incubated at
37°C for 2 h in complete media containing Collagenase A, DNase
I, and glass beads. After digestion, cells were filtered, washed,




















resuspended in 44% Percoll, and layered on Lympholyte-M as
described for spleen cells above. Banded cells were harvested,
washed, and counted. Cells were pooled from two animals. ASC
ELISPOT analysis was modified from previous reports (54, 55).
Statistical Analysis. Antibody titers and ASC numbers were eval-
uated for statistically significant differences by either the
ANOVA or Mann–Whitney tests (INSTAT; GraphPad, San Di-
ego). P  0.05 was considered significant.
Additional Methods. See Supporting Text, which is published as
supporting information on the PNAS web site, for more detailed
methods.
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